Logo Image
News
Global BulletinAll NewsFDA Approval AlertWomen in Oncology
Watch
Expert ConversationsShows & PodcastsNews & Analysis
Conferences
Publications
All JournalsEditorial BoardFor AuthorsYear in Review
More
Events
Frontline ForumSatellite Sessions
CME/CE
Resources
Awareness MonthThe Bispecifics NetworkNurse Practitioners/Physician's AssistantsPartnersSponsoredSponsored Media
Career Center

Subscribe

  • News
  • Watch
  • Conferences
  • Publications
  • Events
  • CME/CE
  • Resources
  • Career Center
  • Subscribe
  • Adverse Effects
  • Artificial Intelligence
  • Brain Cancer
  • Breast Cancer
    • HER2-Positive Breast Cancer
    • Triple-Negative Breast Cancer
  • Gastrointestinal Cancer
    • Colorectal Cancer
    • Esophageal Cancer
    • Pancreatic Cancer
    • Gastric Cancer
    • Liver Cancer
  • Genitourinary Cancers
    • Kidney Cancer
    • Bladder Cancer
    • Prostate Cancer
  • Gynecologic Cancers
    • Endometrial Cancer
    • Ovarian Cancer
    • Cervical Cancer
  • Head & Neck Cancer
  • Hematologic Oncology
    • Multiple Myeloma
    • Myelodysplastic Syndromes
    • Myeloproliferative Neoplasms
  • Infection
    • Vaccines
  • Leukemia
  • Lung Cancer
    • Small Cell Lung Cancer (SCLC)
    • Non-Small Cell Lung Cancer (NSCLC)
  • Lymphoma
  • Neuroendocrine Tumors
  • Oncology
  • Pediatric Cancers
  • Psycho-Oncology
  • Radiation Oncology
  • Sarcoma
  • Screening
  • Skin Cancer & Melanoma
  • Surgery
  • Thyroid Cancer
Spotlight -
Psycho-Oncology|
Artificial Intelligence|
Career Center|
Radiation Oncology|
Surgery
Advertisement

Alexandra Ford

Advertisement

Articles by Alexandra Ford

47 Can We Identify Factors That Predict DCIS Upgrade to Invasive Cancer at Mastectomy?

ByKelly Mackessy,Christopher Verdone,Karisa Beebe,Valerie L. Staradub, MD,Candice Ford,Kristen Skonieczny,Alexandra Haraczy,Alexandra Ford,Hyeon Jeong,Esha Parikh,Dawn Johnson Leonard
May 24th 2024
Advertisement

Latest Updated Articles



    Advertisement
    Advertisement

    Trending on CancerNetwork

    1

    Pasritamig Plus JNJ-9401 Yields 73% PSA Response in Metastatic CRPC

    2

    Azacitidine Plus Ruxolitinib Shows Durable Responses in Myelofibrosis

    3

    Nogapendekin Alfa/BCG Earns Israeli Approval in BCG-Unresponsive NMIBC

    4

    Building Systems to Catch Liver and Other Cancers in Patients With MASLD

    5

    PIKTOR Plus Paclitaxel Yields Responses in Pretreated PAM-Mutated Endometrial Cancer

    • About
    • Advertise
    • CureToday.com
    • OncLive.com
    • OncNursingNews.com
    • TargetedOnc.com
    • Editorial
    • Contact
    • Terms and Conditions
    • Privacy
    • Do Not Sell My Personal Information
    Contact Info

    259 Prospect Plains Rd, Bldg H
    Cranbury, NJ 08512

    Brand Logo

    © 2026 MJH Life Sciences®

    All rights reserved.

    Home
    About Us
    News
    Contact Us